Danielle M. Burgenske

This study explores optimizing aptamer-drug conjugates for GBM treatment by focusing on internalization and tumor homing through in vivo SELEX, but faces challenges with tumor specificity.

The paper introduces INSIGHT, a platform for phosphoproteomic analysis of rare cell subpopulations, and applies it to study signaling changes in disseminated glioblastoma cells in vivo.

This study develops and tests DNA aptamer-drug conjugates (ApDCs) for glioblastoma treatment using an in vivo SELEX approach in a patient-derived xenograft model.

The paper integrates single-cell RNA sequencing data with drug response signatures to identify drug-sensitive and resistant glioblastoma cell states and predict synergistic drug combinations.

This study uses a multi-omics approach to analyze early TMZ responses in GBM cells, identifying TMZ-associated peptide antigens and immune-related changes.

The paper quantifies tyrosine phosphorylation in FFPE tissues to reveal patient-specific signaling networks and identifies oncogenic kinases in cancer tumors.

The paper identifies four molecularly distinct glioblastoma subtypes using single-cell protein-activity analysis and shows drug sensitivity is state-dependent.